{"id":32642,"date":"2023-12-07T18:22:00","date_gmt":"2023-12-07T18:22:00","guid":{"rendered":"https:\/\/news.pakistaninewspaperlist.com\/dry-eye-disease-market-to-register-immense-growth-during-the-study-period-2019-2032-estimates-delveinsight-leading-companies-brim-ocular-iacta-abbvie-novartis-kowa-sylentis-palat\/"},"modified":"2023-12-07T18:22:00","modified_gmt":"2023-12-07T18:22:00","slug":"dry-eye-disease-market-to-register-immense-growth-during-the-study-period-2019-2032-estimates-delveinsight-leading-companies-brim-ocular-iacta-abbvie-novartis-kowa-sylentis-palat","status":"publish","type":"post","link":"https:\/\/pakistaninewspaperlist.com\/news\/dry-eye-disease-market-to-register-immense-growth-during-the-study-period-2019-2032-estimates-delveinsight-leading-companies-brim-ocular-iacta-abbvie-novartis-kowa-sylentis-palat\/","title":{"rendered":"Dry Eye Disease Market to Register Immense Growth During the Study Period (2019\u20132032), Estimates DelveInsight | Leading Companies &#8211; BRIM, Ocular, Iacta, AbbVie, Novartis, Kowa, Sylentis, Palatin, Yuyu, Mimetogen"},"content":{"rendered":"<div id=\"main-body-container\" itemprop=\"articleBody\">\n<p align=\"justify\">New York, USA, Dec.  07, 2023  (GLOBE NEWSWIRE) &#8212; <strong>Dry Eye Disease Market to Register Immense Growth During the Study Period (2019\u20132032), Estimates DelveInsight | Leading Companies &#8211; BRIM, Ocular, Iacta, AbbVie, Novartis, Kowa, Sylentis, Palatin, Yuyu, Mimetogen\u00a0<\/strong><\/p>\n<p align=\"justify\"><strong><em>Several approved therapies drive the current therapeutic landscape of dry eye disease in the 7MM. The dry eye disease market is estimated to increase by 2032. The major reason for this besides the approved products will be the launch of emerging therapies, during the forecast period (2023\u20132032).\u00a0<\/em><\/strong><\/p>\n<p align=\"justify\">DelveInsight\u2019s <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Xzakyl-Us2fItG76Ww7X-eSwIXcT6ZOm4nwoAO2ov87a0iFHOjnwV7cVuIubI0wE9S52OBbSt9pIQraTwzwT0U-L2x0qWpC1LCD0bvDGGRi00tG4KCw3NvBDg8Z1boqiratmYqseRHW1wArvRgsiriSqSQRtN02pngh8pvOavba0yVpL_pr2g22Y2x-13MbfU8RaEMfERe0k1cfJ80wvNvgSC3OgHSfJi5ntEXrOYaZt8Q6y_K7PgyIRHKgZv4R4dpQCMqzatGVWH1UV1ucQwA==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><strong>Dry Eye Disease Market Insights<\/strong><\/a> report includes a comprehensive understanding of current treatment practices, dry eye disease emerging drugs, market share of individual therapies, and current and forecasted dry eye disease market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].<\/p>\n<p align=\"justify\"><strong>Key Takeaways from the Dry Eye Disease Market Report<\/strong><\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:12pt; margin-bottom:0.0001pt; text-align:justify;\">As per DelveInsight\u2019s analysis, the dry eye disease market is anticipated to grow at a significant CAGR by 2032.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">According to DelveInsight\u2019s analysis, in 2022, females account for a higher number of dry Eye disease cases than males in the US.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Leading dry eye disease companies such as<strong> BRIM Biotechnology Inc., Ocular Therapeutix, Inc., Iacta Pharmaceuticals, AbbVie, Novartis Pharmaceuticals, Kowa Research Institute, Inc., Sylentis, S.A., Domp\u00e9 Farmaceutici S.p.A, Aerie Pharmaceuticals, Palatin Technologies, Inc, Yuyu Pharma, Inc., Mimetogen Pharmaceuticals USA, Inc., <\/strong>and others are developing novel dry eye disease drugs that can be available in the dry eye disease market in the coming years.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Some of the key therapies for dry eye disease treatment include <strong>BRM421, OTX-DED, IC265, ABBV-444, Lifitegrast, K-161, Tivanisiran sodium, Oxervate, AR-15512, PL9643, YP-P10, Tavilermide<\/strong><strong>, <\/strong>and others.\u00a0<\/li>\n<\/ul>\n<p align=\"justify\">Discover which therapies are expected to grab the dry eye disease market share @ <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Xzakyl-Us2fItG76Ww7X-eSwIXcT6ZOm4nwoAO2ov84R04xkQJfX0lZIk9c2yUVW3WAsxkE5L9MSWCs4pSJBj5xW6Rk2Hkn1SJH__S1gOusscWHG7CBmYxVB3rEX_QVj6JkUj6An6MC1Tslfe8Mj980n-R_Vlv2RKapYeAG1-dlHSCjlPccBag2FcFvpO6BWkLcT3gpvoGVZu9OWzrDJfNl_xj6_ouXyRNOT9MHRPMM65yu_sOQQsZyQRZxpQwbhx8YgEnTLp5pE8uhTDoc0pQ==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><strong>Dry Eye Disease Market Report<\/strong><\/a><\/p>\n<p align=\"justify\"><strong>Dry Eye Disease Overview<\/strong><\/p>\n<p align=\"justify\">Dry eye disease (DED), also known as dry eye syndrome (DES) or keratoconjunctivitis sicca (KCS), is a prevalent condition characterized by insufficient tear production or rapid tear evaporation. Tears play a vital role in lubricating and nourishing the eyes, and when lacking, DED can result in dryness, redness, swelling, and irritation. Dry eye disease causes include reduced tear production, excessive tear evaporation, and abnormalities in mucus or lipid production. Common dry eye disease symptoms encompass a dry, gritty sensation, burning, itching, a feeling of a foreign body, excessive tearing, eye pain, redness, and occasional photophobia. Environmental factors such as low humidity and high temperatures can exacerbate symptoms, leading to complications like tiny eye abrasions. In advanced cases, the epithelium undergoes pathological changes, including squamous metaplasia and loss of goblet cells.<\/p>\n<p><\/p>\n<p align=\"justify\"><strong>Dry Eye Disease Epidemiology Segmentation<\/strong><\/p>\n<p align=\"justify\">The dry eye disease epidemiology section provides insights into the historical and current dry eye disease patient pool and forecasted trends for the 7MM. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.<\/p>\n<p align=\"justify\">The <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=2eSujF6zp4jqR3q92Q0v6smLsux-0rVi_rwf5YHSU2Ex7GQNw0p3yTJaO4yCqbegiEMg7rP85VtcOiuYKPPbTBKcbGNlewy9JiUAt_NwOBN-FKtK-YkHvC9K4RirPzrJ9KScUtK8rwmmcZkrBU0yvytunk_u3E68SkT_vtjrY7UIoApaDOUheIuRrqI7-kxo15reiZoGyN9bvvj62COW5AKCnsckzITiSCAhE1vWkj3FCORU0nf88pfyziVAUvf7f99KcvJ5B21ffCx8l_y2Cw==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><strong>dry eye disease market report<\/strong><\/a> proffers epidemiological analysis for the study period 2019\u20132032 in the 7MM segmented into:<\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:12pt; margin-bottom:0.0001pt; text-align:justify;\">Total Prevalent Cases of Dry Eye Disease\u00a0<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Total Diagnosed Prevalent Cases of Dry Eye Disease<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Type-specific Diagnosed Prevalent Cases of Dry Eye Disease<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Severity-specific Diagnosed Prevalent Cases of Dry Eye Disease<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Gender-specific Diagnosed Prevalent Cases of Dry Eye Disease<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Age-specific Diagnosed Prevalent Cases of Dry Eye Disease<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Treated Cases of Dry Eye Disease<\/li>\n<\/ul>\n<p align=\"justify\">Download the report to understand which factors are driving dry eye disease epidemiology trends @ <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Xzakyl-Us2fItG76Ww7X-Z6gZGuKsVFwOEtSSfJUI3wSqYuTEh5ThhjU12lU_mCcMLbyr8yNyEQeMxuLkZ7j5tekaBPElV3LjdKjN-85wrDILBkQnJreMqTnpUG4BWMTiLqWLki8vY4bp0vov-i6RoPj2rsCZ_8toF0yGQQn7UcXSaZQmIoMOn8nK2574MuXZAHnXfltmhrOxucPPsNtaBW9zBa8avhSWTppWBqCvhjqoyBkH8KR-MrAxNp66AU9pMDCXZ8T5e_0Tzm1Q8htqA==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><strong>Dry Eye Disease Epidemiological Insights<\/strong><\/a><\/p>\n<p align=\"justify\"><strong>Dry Eye Disease Treatment Market\u00a0<\/strong><\/p>\n<p align=\"justify\">The management strategies for dry eye disease are diverse. The primary objectives of dry eye disease treatment include alleviating dry eye symptoms, enhancing patient comfort, restoring the normal state of the ocular surface and tear film, and, where possible, preventing corneal damage. Dry eye disease treatment modalities span a spectrum from patient education, environmental or dietary adjustments, and the use of artificial tear substitutes to the insertion of punctual plugs, as well as the administration of topical and\/or systemic anti-inflammatory medications. In certain cases, surgical interventions may also be considered. Traditionally, dry eye disease was attributed mainly to tear insufficiency, prompting treatments involving tear replacement products or the conservation of tears through punctual plugs. However, contemporary approaches now encompass methods designed to stimulate tear production.<\/p>\n<p align=\"justify\">In May 2023, the US FDA granted approval for <strong>Bausch and Lomb&#8217;s MIEBO (perfluorohexyloctane ophthalmic solution)<\/strong> to treat the signs and symptoms of dry eye disease. This milestone marks the first FDA-approved eye drop specifically designed to address tear evaporation rather than tear formation. Developed by Novaliq, Bausch + Lomb secured exclusive licensing rights in the US back in 2019. Perfluorohexyloctane, a key component of the drug, creates a monolayer at the air-liquid interface of the tear film, with the anticipated benefit of reducing evaporation.<\/p>\n<p align=\"justify\">Learn more about the FDA-approved drugs for dry eye disease @ <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Gc1Fpi0jU14YQ93rmZY6wgb34Nbl_PfjE9vwAQHo3Yqih-yrtKBmHjJ3gN7FQ9xwkaEVpifx7gVRCe3wNuV7K53VFCSX5mltK1lFkRihlLZW5vlAP5ngIfVf5pOWqPpG97P8D4FbHyCBInWZ6eR-g7UYl0LXI8ycrqaLcjo2nMf1wGZPfaxhGT0RsUA6Rb-2t1e44w9TAPHv83MbI9vfK7nHKehuvWsDvGrdQGeN5RtbChf5-YeRLkuKYfxJmAFVSQWmtPSRooWK9nxZumNv7g==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><strong>Drugs for<\/strong> <strong>Dry Eye Disease Treatment<\/strong><\/a><strong>\u00a0<\/strong><\/p>\n<p align=\"justify\"><strong>Key Dry Eye Disease Therapies and Companies<\/strong><\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:12pt; margin-bottom:0.0001pt; text-align:justify;\">BRM421: BRIM Biotechnology Inc.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">OTX-DED: Ocular Therapeutix, Inc.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">IC265: Iacta Pharmaceuticals<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">ABBV-444: AbbVie<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Lifitegrast: Novartis Pharmaceuticals<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">K-161: Kowa Research Institute, Inc.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Tivanisiran sodium: Sylentis, S.A.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Oxervate: Domp\u00e9 Farmaceutici S.p.A<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">AR-15512: Aerie Pharmaceuticals<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">PL9643: Palatin Technologies, Inc<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">YP-P10: Yuyu Pharma, Inc.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Tavilermide: Mimetogen Pharmaceuticals USA, Inc.<\/li>\n<\/ul>\n<p align=\"justify\">To know more about dry eye disease clinical trials, visit @ <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Xzakyl-Us2fItG76Ww7X-RdYjkjDDrYkLc6X_MJK5oqC3KLhbUDQgWtR20nleMDlVij4l3IZpU8ylon5A4-hJQYrzzJJRlSK1-qUKXrBz4DO8U25SrWdYJLw4XLuneCxoFY86fM8sX4SOX1H6bnw5tFdiqCsuYvcTPGj_69kCmppCGSB0lCk_hnDnskWtySYrShHqtG0D50RO3rsHeyenc2hyTungx3xj634yovJLwEtbBnYp8XkqXXwYxg5hb7A5sqDPZoqVHKY5uiQVc2Gtg==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><strong>Dry Eye Disease Treatment Drugs<\/strong><\/a><strong>\u00a0<\/strong><\/p>\n<p align=\"justify\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Xzakyl-Us2fItG76Ww7X-eSwIXcT6ZOm4nwoAO2ov85au6JNbKD4u0JwvRg9qe43_9cnDAfUvJwkNG9PTrbmxSx8FP1YjGOFkOkIE4BdAbC4-joFWZ7FVnRzfLPrAS4l59f3UR0h2KJ2NIpmdZUrisOBhBiQrxlWVFyem3e_3s4RYgdq2rMzSu3zpf-7smfF-WkIjoExVIW_YJNvlSphKQVPc5k9dPybDKPoSmYe-aKOakKyzU-B5cqeBDCMWzYm1YTD1WRExV0qitJaFMCAEA==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><strong>Dry Eye Disease Market Dynamics<\/strong><\/a><\/p>\n<p align=\"justify\">The dry eye disease market dynamics are anticipated to change in the coming years. As an increasingly recognized ocular health concern, the dry eye disease market is witnessing a <strong>surge in research and development activities<\/strong> aimed at introducing innovative therapies. <strong>Lifestyle changes<\/strong>, prolonged screen time, and environmental factors contribute to the <strong>rising incidence of dry eye disease<\/strong>, expanding the potential consumer base for related pharmaceuticals and treatments. Furthermore, the dry eye disease market is shaped by a<strong> growing awareness<\/strong> among healthcare professionals and patients, leading to early diagnosis and intervention. The <strong>competition among pharmaceutical companies<\/strong> to develop effective and convenient treatment modalities, such as novel eye drops or sustained-release formulations, adds an element of dynamism to the dry eye disease market.<\/p>\n<p align=\"justify\">Furthermore, many potential therapies are being investigated for the treatment of dry eye disease, and it is safe to predict that the treatment space will significantly impact the dry eye disease market during the forecast period. Moreover, the <strong>anticipated introduction of emerging therapies<\/strong> with improved efficacy and a further <strong>improvement in the diagnosis rate<\/strong> are expected to drive the growth of the dry eye disease market in the 7MM.<\/p>\n<p align=\"justify\">However, several factors may impede the growth of the dry eye disease market. Regulatory hurdles pose a significant challenge, as the <strong>approval process for new treatments<\/strong> requires rigorous testing and compliance with stringent standards. The <strong>complexity of ocular physiology<\/strong> and the <strong>need for targeted drug delivery systems<\/strong> present scientific challenges, requiring substantial investment in research and development. Additionally, the crowded landscape of ocular health products and treatments demands a robust differentiation strategy for new entrants.\u00a0<\/p>\n<p align=\"justify\">Moreover, dry eye disease treatment poses a <strong>significant economic burden<\/strong> and disrupts patients\u2019 overall well-being and QOL. Furthermore, the dry eye disease market growth may be offset by <strong>failures and discontinuation of emerging therapies<\/strong>, <strong>unaffordable pricing<\/strong>, <strong>market access and reimbursement issues<\/strong>, and a <strong>shortage of healthcare specialists<\/strong>. In addition, the <strong>undiagnosed, unreported cases and the unawareness<\/strong> about the disease may also impact the dry eye disease market growth.<\/p>\n<table style=\"border-collapse: collapse; border-collapse:collapse ;\">\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \"><strong>Dry Eye Disease Report Metrics<\/strong><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \"><strong>Details<\/strong><\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Study Period<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">2019\u20132032<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Dry Eye Disease Report Coverage<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Key Dry Eye Disease Companies<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">BRIM Biotechnology Inc., Ocular Therapeutix, Inc., Iacta Pharmaceuticals, AbbVie, Novartis Pharmaceuticals, Kowa Research Institute, Inc., Sylentis, S.A., Domp\u00e9 Farmaceutici S.p.A, Aerie Pharmaceuticals, Palatin Technologies, Inc, Yuyu Pharma, Inc., Mimetogen Pharmaceuticals USA, Inc., and others<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Key Dry Eye Disease Therapies<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">BRM421, OTX-DED, IC265, ABBV-444, Lifitegrast, K-161, Tivanisiran sodium, Oxervate, AR-15512, PL9643, YP-P10, Tavilermide, and others<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\"><strong>Scope of the <\/strong><strong>Dry Eye Disease<\/strong><strong> Market Report<\/strong><\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:12pt; margin-bottom:0.0001pt; text-align:justify;\"><strong>Dry Eye Disease Therapeutic Assessment: <\/strong>Dry Eye Disease current marketed and emerging therapies<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\"><strong>Dry Eye Disease<\/strong> <strong>Market Dynamics:<\/strong> Attribute Analysis of Emerging Dry Eye Disease Drugs<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\"><strong>Competitive Intelligence Analysis:<\/strong> SWOT analysis and Market entry strategies<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\"><strong>Unmet Needs, KOL\u2019s views, Analyst\u2019s views, Dry Eye Disease Market Access and Reimbursement<\/strong><\/li>\n<\/ul>\n<p align=\"justify\">Discover more about dry eye disease drugs in development @ <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Xzakyl-Us2fItG76Ww7X-ZlUO9luB_0pxe1f7SeCt3GwdX4zwKJyXtdK7dKsz9HVzWhgvJ4Ut9h4Ppwxu3jcZ7I8YRkU7aVFp2gigua9vVbIqD05hWh6FciR1ibeRvICwIYsy3PhoCaNz_w4Wc0ocPwLlsp092zDYw37yA0VpV0JIonTNKlwjzvx0cUe_N8spcHGsliyqL_k0O2WchEN9iwsAeJwmvC1U57pRvwTYQ07ppFFSrKmR8AfzciOKxW_P6-59CTRExzzqsWcoCPLVQ==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><strong>Dry Eye Disease Clinical Trials<\/strong><\/a><\/p>\n<p align=\"justify\"><strong>Table of Contents<\/strong><\/p>\n<table style=\"border-collapse: collapse; border-collapse:collapse ;\">\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">1.<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Dry Eye Disease Market Key Insights<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">2.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Dry Eye Disease Market Report Introduction<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">3.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Dry Eye Disease Market Overview at a Glance<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">4.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Dry Eye Disease Market Executive Summary<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">5.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Disease Background and Overview<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">6.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Dry Eye Disease Treatment and Management<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">7.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Dry Eye Disease Epidemiology and Patient Population<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">8.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Patient Journey<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">9.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Dry Eye Disease Marketed Drugs<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">10.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Dry Eye Disease Emerging Drugs<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">11.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Seven Major Dry Eye Disease Market Analysis<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">12.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Dry Eye Disease Market Outlook<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">13.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Potential of Current and Emerging Therapies<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">14.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">KOL Views<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">15.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Unmet Needs<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">16.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">SWOT Analysis<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">17.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Appendix<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">18.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">DelveInsight Capabilities<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">19.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Disclaimer<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">20.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">About DelveInsight<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\"><strong>Related Reports<\/strong><\/p>\n<p align=\"justify\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Xzakyl-Us2fItG76Ww7X-Z6gZGuKsVFwOEtSSfJUI3xha9jbRHuPEPNjRSBZckJD_z6XC_Prll-oU9DpdFL-3p-v3pSVq4C0S-0l3dUi9DmFHp1IgRjQ3JD6ox78I5HzkpcAW2BsXxh8zM1dy1_BU-TVpzPRI0xBCrdCLnZpRTeiOZeRv32_4sARc0BDWIashIGW6X7b1upq9PjZvDaSsUF6Pkzjm1Oc3SOPOM7SeBZbqgD7zAnMFO_bBezwarEAFIiY-ARDaiZkV2XrCHU77Q==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><strong>Dry Eye Disease Epidemiology Forecast<\/strong><\/a><\/p>\n<p align=\"justify\"><strong>Dry Eye Disease Epidemiology Forecast \u2013 2032<\/strong> report delivers an in-depth understanding of the disease, historical and forecasted dry eye disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n<p align=\"justify\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Xzakyl-Us2fItG76Ww7X-QeEMXbG5hjPL9ekCZQcbvt9f4xiJJz6TY22P1SZHGVNzdrhMal3t_dixbm4X1d5IWC9fzk4gNg8qCVt_fxblwcyy_0Yb4nC7uvb4EIV1hYyYHjdIdL_zauqGGqTUX-7IzWjMBf9R23-uqGZZkfbHlcCoTbydx9b9wqor12ZVMkuQaKzbHttDyz6oYwVhk5xaEsHePTbOcSBNpr77Il0L_dHc0e9_O4JGspEA0S_xf0N\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><strong>Dry Eye Disease Pipeline<\/strong><\/a><\/p>\n<p align=\"justify\"><strong>Dry Eye Disease Pipeline Insight <\/strong><strong>\u2013 2023<\/strong> report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key dry eye disease companies, including <strong>Alcon, HanAll Biopharma, Ocular Therapeutix, Seinda Pharmaceutical, IVIEW Therapeutics, Novaliq GmbH, Kowa Company, Seikagaku Corporation, Aramis Biosciences, Dreamhawk Vision Biotech, Inc., Taejoon Pharmaceutical, Quorum Innovations, Serentrix, Noveome, Allysta Pharmaceuticals, BRIM Biotechnology, Invirsa,\u00a0 <\/strong>among others.<\/p>\n<p align=\"justify\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Or7eQVCnnutKTdXWc9wRjAgZDHQB0y5oXOv59C6OEDkn4n_PtbkJAw5TWt971UouZ_GT-s2KU3TjWKu-AiyUGCcbXEXdIjsg6xpzQmr-FTQ5pm2DkcxNJ6qg8YMfx47jnnwAWg54vO02PHzJrz4-fN_miacmxevdBII2RUY7TEeSmttIUGgZ7EbfdUbMpOdl8bVUVRpLlyRUqC_Au-v1kukMtM9Qc44RzTFvLCc_-alb0Ia0iVgThgf-yM-GnLr7\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><strong>Moderate Dry Eye Market<\/strong><\/a><\/p>\n<p align=\"justify\"><strong>Moderate Dry Eye Market Insights, Epidemiology, and Market Forecast <\/strong><strong>\u2013 2032 <\/strong>report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key moderate dry eye companies, including <strong>Alcon, HanAll Biopharma, Ocular Therapeutix, Seinda Pharmaceutical, IVIEW Therapeutics, Novaliq GmbH, Kowa Company,<\/strong> among others.<\/p>\n<p align=\"justify\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=MO2TivPBVefBdphFM14rsOnPG3Zf-vEkZUTIk3wu8IxFtk7Rsu96cQJvxGSMjuroM_mdjJt4XZ_phxR4SA18AYyFEJ9puzjAwVnAzMg5VQf3o7acvKH3tmlqHjFkfqBRBvZcd05NiVQaAzI94PsfuWii5kvrkGe0kLPfI1PSQ7TWi56jMgHzUhvflgXQZTKKEux5wWaiNAacI7epgVH5Bm5a8qGHcGQ9llJZQdzEmio=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><strong>Mild Dry Eye Market<\/strong><\/a><\/p>\n<p align=\"justify\"><strong>Mild Dry Eye Market Insights, Epidemiology, and Market Forecast <\/strong><strong>\u2013 2032 <\/strong>report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key mild dry eye companies, including <strong>Aramis Biosciences, Dreamhawk Vision Biotech, Inc., Taejoon Pharmaceutical, Quorum Innovations,<\/strong> among others.<\/p>\n<p align=\"justify\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=bD9I7dmjTPP_z3HGACJZcih2lokDL6xvBx5npGa39SXNVvDuhHTl7op7xvRGmo6EhrN1b-A2IpQ4TWN7jJJnknZReeb7Ov9j2ddLSzCmPVY8XJNU_iUwdvq_inJ_2bfRf-i9W9bWtLDJuAtrEqNGtNs-JsU3gQTM4bMmrZlZf66ygPc5DIsAsU3KRMwwerA_2gWCYEvjt8aOJImoYhk9SBrtvyEGz45mJgLiV_xElIM=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><strong>Severe Dry Eye Market<\/strong><\/a><\/p>\n<p align=\"justify\"><strong>Severe Dry Eye Market Insights, Epidemiology, and Market Forecast <\/strong><strong>\u2013 2032 <\/strong>report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key severe dry eye companies, including <strong>Taejoon Pharmaceutical, Quorum Innovations, Serentrix, Noveome, Allysta Pharmaceuticals, BRIM Biotechnology, Invirsa,<\/strong> among others.<\/p>\n<p align=\"justify\"><strong>About\u00a0DelveInsight<\/strong><\/p>\n<p align=\"justify\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.\u00a0Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform\u00a0PharmDelve<strong>.<\/strong><\/p>\n<p align=\"justify\"><strong>Connect with us on<\/strong><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=sC25TF1qJAzH-XdhTZeVp3nUZtM5j9KYcDIin2hnRPRGxrAiMOQHp5RVsKOMuseZs70V-tbi35Zgk8_yQKyHfyIoaDLfoboEZSnOZ-ETMz-l4Zso4lSJbpI9uqRaNXmnP-2pU8mRnEOd08u9ah7Flg==\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"> <strong>LinkedIn<\/strong><\/a><strong>|<\/strong><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=I2FcPF2IWOeeWCFXUxND96tesb6GLhHf5C4J0DyaCPrvVkQPSC4E3gyrDWhOWNKi_3Zmqej72I92LMTkhQ8r8KZr49DTfuXC7aQhZVLkWTw=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><strong>Facebook<\/strong><\/a><strong>|<\/strong><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=q9NzN6NVlhRZrGHvuoRyHlCeIyafYF_13FkrpYm6qd_eStEEjV1pFW2CAxMyHLU3gd5wJBHbRlHIJPyo8Nb4HKFPQBatULDIUd9itztUDnM=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><strong>Twitter<\/strong><\/a><\/p>\n<pre\/><img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ODhmOGNjYzQtYTJiOS00NzI5LTkxZGQtMTUzMDE5YmM4YzNmLTEyMDQ5Mzg=\/tiny\/DelveInsight-Business-Research.png\" referrerpolicy=\"no-referrer-when-downgrade\"\/>\n            <\/div>\n","protected":false},"excerpt":{"rendered":"<p>New York, USA, Dec. 07, 2023 (GLOBE NEWSWIRE) &#8212; Dry Eye Disease Market to Register Immense Growth During the Study Period (2019\u20132032), Estimates DelveInsight | Leading Companies &#8211; BRIM, Ocular, Iacta, AbbVie, Novartis, Kowa, Sylentis, Palatin, Yuyu, Mimetogen\u00a0 Several approved therapies drive the current therapeutic landscape of dry eye disease in the 7MM. The dry [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":32643,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"fifu_image_url":"https:\/\/ml.globenewswire.com\/Resource\/Download\/dbcddd65-71dd-4559-8875-ae89ac4f96db","fifu_image_alt":"","footnotes":""},"categories":[208],"tags":[],"class_list":["post-32642","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-globenewswire"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/posts\/32642","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/comments?post=32642"}],"version-history":[{"count":0,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/posts\/32642\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/media\/32643"}],"wp:attachment":[{"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/media?parent=32642"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/categories?post=32642"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pakistaninewspaperlist.com\/news\/wp-json\/wp\/v2\/tags?post=32642"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}